| (USD) | Jun 2023 | Q/Q |
|---|---|---|
| Revenue | 583K | -20% |
| Operating Income | -10.1MM | -12% |
| Operating Expenses | 10.7MM | -13% |
| Net Income | -10MM | -10% |
| R&D | 6.6MM | +13% |
| G&A | 3.8MM | -37% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
On September 12, 2023, Adelene Perkins, a director at Infinity Pharmaceuticals Inc, sold 410,196 shares of the company.
Cambridge biotech Infinity Pharmaceuticals is clearing out its C-suite in the wake of a failed merger agreement that had already cost 21 jobs.
A Cambridge biotech is laying off most of its staff in the wake of a failed merger agreement. Infinity Pharmaceuticals Inc. (Nasdaq: INFI) announced after market close on Tuesday that it would be letting go of 21 people — about 78% of its workforce, which would leave just six staffers. Infinity had been set to reverse these fortunes by merging with another company, MEI Pharma Inc. (Nasdaq: MEIP).
CAMBRIDGE, Mass., July 25, 2023--Infinity Pharmaceuticals today announced a series of actions designed to reduce burn rate and enhance ability to maximize value of eganelisib
CAMBRIDGE, Mass., July 24, 2023--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI").
CAMBRIDGE, Mass., July 14, 2023--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI") at the special meeting of Infinity stockholders held earlier today (the "Special Meeti
CAMBRIDGE, Mass., July 10, 2023--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced further design features of its Phase 2 MARIO-8 study in SCCHN.
CAMBRIDGE, Mass., July 05, 2023--Infinity Pharmaceuticals announced today that ISS has recommended that Infinity stockholders vote for the merger with MEI Pharma, Inc.
SAN DIEGO & CAMBRIDGE, Mass., June 15, 2023--MEI Pharma, Inc. (Nasdaq: MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern Ti
CAMBRIDGE, Mass., April 13, 2023--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced upcoming presentations including data on eganelisib by Infinity’s collaborator, Professor Judith A. Varner of the UCSD Moores Cancer Center, La Jolla, California, at the 2023 Annual Meeting of the American Association of Ca